1. Home
  2. KTTA vs HIND Comparison

KTTA vs HIND Comparison

Compare KTTA & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.44

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Logo Vyome Holdings Inc.

HIND

Vyome Holdings Inc.

N/A

Current Price

$2.03

Market Cap

15.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
KTTA
HIND
Founded
2020
2017
Country
United States
United States
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
15.2M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
KTTA
HIND
Price
$0.44
$2.03
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $8.83
AVG Volume (30 Days)
★ 141.8K
15.8K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 77.07
64.86
EPS
N/A
★ N/A
Revenue
★ $486,559.00
$319,714.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$82.65
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 3130.37
24.43
52 Week Low
$0.28
$1.75
52 Week High
$2.06
$6.56

Technical Indicators

Market Signals
Indicator
KTTA
HIND
Relative Strength Index (RSI) 35.47 46.32
Support Level $0.43 $1.86
Resistance Level $0.52 $2.31
Average True Range (ATR) 0.03 0.11
MACD -0.01 0.01
Stochastic Oscillator 9.01 30.42

Price Performance

Historical Comparison
KTTA
HIND

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: